HeXun Biosciences Statistics
Total Valuation
HeXun Biosciences has a market cap or net worth of TWD 3.39 billion. The enterprise value is 3.15 billion.
Market Cap | 3.39B |
Enterprise Value | 3.15B |
Important Dates
The last earnings date was Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
HeXun Biosciences has 46.00 million shares outstanding. The number of shares has increased by 10.22% in one year.
Current Share Class | n/a |
Shares Outstanding | 46.00M |
Shares Change (YoY) | +10.22% |
Shares Change (QoQ) | -0.16% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 27.33.
PE Ratio | 27.33 |
Forward PE | n/a |
PS Ratio | 14.35 |
PB Ratio | 6.16 |
P/TBV Ratio | n/a |
P/FCF Ratio | 112.02 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.94, with an EV/FCF ratio of 103.96.
EV / Earnings | 25.33 |
EV / Sales | 13.31 |
EV / EBITDA | 22.94 |
EV / EBIT | 27.06 |
EV / FCF | 103.96 |
Financial Position
The company has a current ratio of 12.69, with a Debt / Equity ratio of 0.06.
Current Ratio | 12.69 |
Quick Ratio | 12.11 |
Debt / Equity | 0.06 |
Debt / EBITDA | 0.25 |
Debt / FCF | 1.12 |
Interest Coverage | 74.05 |
Financial Efficiency
Return on equity (ROE) is 25.43% and return on invested capital (ROIC) is 13.38%.
Return on Equity (ROE) | 25.43% |
Return on Assets (ROA) | 12.81% |
Return on Capital (ROIC) | 13.38% |
Revenue Per Employee | 6.75M |
Profits Per Employee | 3.55M |
Employee Count | 35 |
Asset Turnover | 0.42 |
Inventory Turnover | 2.64 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.82% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +3.82% |
50-Day Moving Average | 74.08 |
200-Day Moving Average | 68.01 |
Relative Strength Index (RSI) | 51.32 |
Average Volume (20 Days) | 44,861 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HeXun Biosciences had revenue of TWD 236.41 million and earned 124.21 million in profits. Earnings per share was 2.70.
Revenue | 236.41M |
Gross Profit | 216.71M |
Operating Income | 116.26M |
Pretax Income | 124.21M |
Net Income | 124.21M |
EBITDA | 133.82M |
EBIT | 116.26M |
Earnings Per Share (EPS) | 2.70 |
Balance Sheet
The company has 277.84 million in cash and 33.76 million in debt, giving a net cash position of 244.08 million or 5.31 per share.
Cash & Cash Equivalents | 277.84M |
Total Debt | 33.76M |
Net Cash | 244.08M |
Net Cash Per Share | 5.31 |
Equity (Book Value) | 550.63M |
Book Value Per Share | 11.97 |
Working Capital | 360.65M |
Cash Flow
In the last 12 months, operating cash flow was 66.73 million and capital expenditures -36.46 million, giving a free cash flow of 30.26 million.
Operating Cash Flow | 66.73M |
Capital Expenditures | -36.46M |
Free Cash Flow | 30.26M |
FCF Per Share | 0.66 |
Margins
Gross margin is 91.67%, with operating and profit margins of 49.18% and 52.54%.
Gross Margin | 91.67% |
Operating Margin | 49.18% |
Pretax Margin | 52.54% |
Profit Margin | 52.54% |
EBITDA Margin | 56.61% |
EBIT Margin | 49.18% |
FCF Margin | 12.80% |
Dividends & Yields
HeXun Biosciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.22% |
Shareholder Yield | -10.22% |
Earnings Yield | 3.66% |
FCF Yield | 0.89% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
HeXun Biosciences has an Altman Z-Score of 30.78.
Altman Z-Score | 30.78 |
Piotroski F-Score | n/a |